The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.75
Bid: 17.50
Ask: 18.00
Change: 0.00 (0.00%)
Spread: 0.50 (2.857%)
Open: 17.75
High: 17.75
Low: 17.75
Prev. Close: 17.75
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

OptiBiotix obtains BRC accreditation

5 Jan 2022 07:00

RNS Number : 4249X
OptiBiotix Health PLC
05 January 2022
 

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

OptiBiotix obtains British Retail Consortium accreditation

One of the leading international food safety standards

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing unique science and human study-based compounds that modulate the microbiome to address metabolic syndrome and diabetes, systemic low-grade inflammation, obesity, cardiovascular disease, high cholesterol and to support healthy aging has achieved British Retail Consortium ('BRC') accreditation.

 

BRC was the first standard to meet the Global Food Safety Initiative ('GFSI') benchmark, which means it is accepted by many of the world's biggest retailers, such as Tesco and Walmart. The certification ensures customers have confidence in OptiBiotix's products and it allows the Company to do business with those retailers, manufacturers, ingredients companies and food service organisations who specify certification as part of their approval process (most large retailers and their suppliers). It incorporates food safety management systems and internationally accepted best practice to ensure the safety and quality of products and in doing so reduces the risk of recalls.

 

René Kamminga, CEO of OptiBiotix Limited, commented: "We are very pleased to announce our BRC accreditation which supports our commercial strategy of selling final product solutions to partners in the retail channel containing our science backed pro and prebiotic ingredients. I am particularly proud of our team which achieved this accreditation in a relatively short period of time."

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07876 741 001

Anna Dunphy

 

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRASSUFWLEESEFF
Date   Source Headline
26th Jun 20187:00 amRNSAgreement with global corporate for SweetBiotix®
21st Jun 20187:00 amRNSExclusive license agreement for LPLDL®
18th Jun 20187:00 amRNSManufacturing agreement with Morley Foods
14th Jun 20187:00 amRNSExercise of Options and Issue of Equity
11th Jun 20187:00 amRNSNotice of AGM
7th Jun 20187:00 amRNSUS launch of LPLDL® with Seed Health
31st May 20187:00 amRNSSweetBiotix® agreement with global dairy company
30th May 20187:00 amRNSPlacing and Issue of Equity
23rd May 20187:00 amRNSFinal Results
22nd May 20187:00 amRNSLP-LDL agreement for USA
18th May 20187:00 amRNSSlimBiome® wins award at Vitafoods 2018
16th May 20184:40 pmRNSHolding(s) in Company
16th May 20187:00 amRNSExclusive manufacturing and supply agreement
8th May 20187:00 amRNSLaunch of extended range of products at Vitafoods
1st May 20187:00 amRNSLP-LDL? news media interest in USA
30th Apr 20187:00 amRNSNotice of Results
24th Apr 20187:00 amRNSSlimBiome non-exclusive UK distribution agreement
19th Apr 20187:00 amRNSAppointment of Head of Online Sales and Marketing
18th Apr 20187:00 amRNSCholBiome exclusive distribution agreement
5th Apr 20187:00 amRNSNew patent filings for SweetBiotix
27th Mar 20187:00 amRNSScientific and commerical update
8th Mar 20187:00 amRNSLaunch of Slimbiome in Nutri-bites
6th Mar 20187:00 amRNSLPLDL® Exclusive European License Agreement
28th Feb 20187:00 amRNSOptiBiotix Capital Reorganisation
6th Feb 20187:00 amRNSExercise of warrant and issue of equity
1st Feb 20182:22 pmRNSDirector's dealing
30th Jan 20183:03 pmRNSExercise of warrant and issue of equity
25th Jan 201811:45 amRNSResult of Meeting
23rd Jan 20187:00 amRNSSweetBiotix® development: human taste studies
17th Jan 20187:00 amRNSPresentation of data at European Conference
8th Jan 20183:12 pmRNSShareholder Circular and Notice of General Meeting
8th Jan 20187:00 amRNSDirectorate Changes
14th Dec 20173:35 pmRNSExercise of warrant and issue of equity
12th Dec 20177:00 amRNSManufacturing, supply & profit sharing agreement
5th Dec 20177:00 amRNSProposed directorate changes
28th Nov 20177:00 amRNSCapital reorganisation
17th Nov 20173:06 pmRNSExercise of Warrant and Issue of Equity
8th Nov 20177:00 amRNSSlimBiome® commercial & product development update
1st Nov 20177:00 amRNSManufacturing, supply & profit sharing agreement
26th Oct 20177:00 amRNSPresentation of research
24th Oct 20177:00 amRNSLPLDL® supply agreement with Galenicum
4th Oct 20177:00 amRNSSuccessful launch of products at Supply Side West
19th Sep 20177:00 amRNSTechnical, regulatory & commercial update
13th Sep 20177:00 amRNSStrategic partnership with Bened Biomedical
11th Sep 201712:00 pmRNSHolding(s) in Company
7th Sep 20177:00 amRNSInvited to present at Expoquimia in Barcelona
6th Sep 20179:30 amRNSInvestor evening
5th Sep 20177:00 amRNSManufacturing Agreement with Tata Chemicals
1st Sep 20172:41 pmRNSExercise of Options and Issue of Equity
30th Aug 20177:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.